Who are AD109's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow, Regadenoson (Lexiscan), Regadenoson peripheral - central, Pharmacological stress agents, Regadenoson peripheral - peripheral.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ad109.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AD109 — Competitive Intelligence Brief

AD109 (AD109) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine A2A receptor antagonist. Area: Oncology.

phase 3 Adenosine A2A receptor antagonist Adenosine A2A receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AD109 (AD109) — Apnimed. AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AD109 TARGET	AD109	Apnimed	phase 3	Adenosine A2A receptor antagonist	Adenosine A2A receptor
Regadenoson myocardial perfusion imaging	Regadenoson myocardial perfusion imaging	University of Colorado, Denver	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
Regadenoson MRI myocardial blood flow	Regadenoson MRI myocardial blood flow	University of Colorado, Denver	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
Regadenoson (Lexiscan)	Regadenoson (Lexiscan)	Brigham and Women's Hospital	marketed	Adenosine A2A receptor agonist	Adenosine A2A receptor
Regadenoson peripheral - central	Regadenoson peripheral - central	Lokien van Nunen	phase 3	Adenosine A2A receptor agonist	Adenosine A2A receptor
Pharmacological stress agents	Pharmacological stress agents	GE Healthcare	phase 3	Cardiac stress agents	Adenosine A2A receptor (adenosine); dopamine and beta-adrenergic receptors (dobutamine); adenosine A2A receptor (regadenoson)
Regadenoson peripheral - peripheral	Regadenoson peripheral - peripheral	Lokien van Nunen	phase 3	Adenosine A2A receptor agonist	Adenosine A2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine A2A receptor antagonist class)

Apnimed · 1 drug in this class
Kyowa Kirin, Inc. · 1 drug in this class
Sosei · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AD109 — Competitive Intelligence Brief. https://druglandscape.com/ci/ad109. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab